Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada-Reference-Cited by-同舟云学术

Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada

Published:2020-11-12 Issue:12 Volume:23 Page:1525-1533
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Nakhaipour Hamid Reza¹^ORCID,Vudumula Umakanth²^ORCID,Khurana Vivek²^ORCID,Sébire Guillaume³^ORCID,Mah Jean K.⁴^ORCID,Pohl Daniela⁵^ORCID,Schecter Robyn¹^ORCID,Adlard Nicholas⁶^ORCID

Affiliation:

1. Novartis Pharmaceuticals Canada Inc, Dorval, Canada

2. Novartis Healthcare Private Limited, Hyderabad, India

3. Child Neurology Division, Montreal Children Hospital, McGill University, Montreal, Canada

4. Division of Pediatric Neurology, Alberta Children's Hospital, University of Calgary, Calgary, Canada

5. Division of Neurology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada

6. Novartis Pharma AG, Basel, Switzerland

Funder

Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1840138

Reference55 articles.

1. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States

2. Multiple sclerosis in children

3. Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey

4. Natural History of Multiple Sclerosis with Childhood Onset

5. Incidence of acquired demyelination of the CNS in Canadian children

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review;Health Economics Review;2024-02-16

2. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment;CNS Drugs;2021-12-23

3. Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-02